Chris Shibutani, senior biotechnology analyst in Goldman Sachs Research, discusses the transition from a Covid-19 pandemic to an endemic, and how biotech companies are preparing for the next stage of vaccines and therapeutics.
This video was recorded on June 22, 2021
This video should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this recording was obtained from publicly available sources, has not been independently verified by Goldman Sachs, may not be current, and Goldman Sachs has no obligation to provide any updates or changes. All price references and market forecasts are as of the date of recording. This video is not a product of Goldman Sachs Global Investment Research and the information contained in this video is not financial research. The views and opinions expressed in this video are not necessarily those of Goldman Sachs and may differ from the views and opinions of other departments or divisions of Goldman Sachs and its affiliates. Goldman Sachs is not providing any financial, economic, legal, accounting, or tax advice or recommendations in this podcast. The information contained in this video does not constitute investment advice or an offer to buy or sell securities from any Goldman Sachs entity to the listener and should not be relied upon to evaluate any potential transaction. In addition, the receipt of this video by any listener is not to be taken to constitute such person a client of any Goldman Sachs entity. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the statements or any information contained in this video and any liability therefore (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed.